Entrectinib for advanced ROS1 fusion-positive non-small cell lung cancer

Prof. Fabrice Barlesi

Integrated analysis of three phase 1 or 2 studies of entrectinib for advanced ROS1 fusion-positive NSCLC found a high level of clinical benefit.